Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935605 · ClinicalTrials.gov registry record
Pulmonary Hypertension in Left Heart Disease
A clinical trial of Pulmonary Hypertension and Pulmonary Vascular Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT05935605: Recruiting study of Pulmonary Hypertension and Pulmonary Vascular Disease, sponsored by Mayo Clinic.
NCT05935605 is a study of Pulmonary Hypertension and Pulmonary Vascular Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 3,000 participants, above the 572-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (424% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05935605, a study of Pulmonary Hypertension and Pulmonary Vascular Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.
Primary Outcome
Peak exercise cardiac output (L/min) will be measured using the direct Fick technique during the invasive hemodynamic assessment by right heart catheterization.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Lung ultrasound
- DIAGNOSTIC_TEST Transthoracic Echocardiography (TTE)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2028-05 |
What NCT05935605 shows while recruiting
NCT05935605 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 572-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (424% higher).
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Lung ultrasound is the first listed.
NCT05935605 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05935605 about?
NCT05935605 is a clinical study titled "Pulmonary Hypertension in Left Heart Disease". The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.
What is the current status of trial NCT05935605?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2023-07-20. Estimated completion is 2028-05.
What conditions does trial NCT05935605 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Vascular Disease, Left Heart Disease.
What interventions are being tested in trial NCT05935605?
The interventions under investigation include: Lung ultrasound (DIAGNOSTIC_TEST), Transthoracic Echocardiography (TTE) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05935605?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05935605 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05935605's enrollment target sits among peer trials
3,000 5th of 72 higher than 67 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI